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ABSTRACT  
Rationale: Use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers 
(ARBs) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with 
hypertension. 
Objective: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in 
COVID-19 patients with hypertension. 
Methods and Results: This retrospective, multi-center study included 1128 adult patients with hypertension 
diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [IQR 55-
68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [IQR 57-
69]; 53.5% men), who were admitted to nine hospitals in Hubei Province, China from December 31, 2019 
to February 20, 2020. Unadjusted mortality rate was lower in the ACEI/ARB group versus the non-
ACEI/ARB group (3.7% vs. 9.8%; P = 0.01). In mixed-effect Cox model treating site as a random effect, 
after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause 
mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted HR, 0.42; 95% 
CI, 0.19-0.92; P =0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables 
in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in 
patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted HR, 0.37; 95% 
CI, 0.15-0.89; P = 0.03). Further subgroup propensity score-matched analysis indicated that, compared to 
use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted HR, 
0.30; 95%CI, 0.12-0.70; P = 0.01) in COVID-19 patients with hypertension.  
Conclusions: Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was 
associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. While study 
interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of 
ACEI/ARB was associated with an increased mortality risk.  
Key Words:  
COVID-19, hypertension, ACEI/ARB, SARS-COV-2, pneumonia, infectious disease, lung.  
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Nonstandard Abbreviations and Acronyms: 
 
 
 
 
 
ACC American College of Cardiology 
ACE Angiotensin-converting enzyme 
ACEI Angiotensin-converting enzyme inhibitor 
AHA American Heart Association 
AIDS Acquired immune deficiency syndrome 
ALT Alanine transaminase 
ARB Angiotensin II receptor blocker 
ARDS Acute respiratory distress syndrome 
AST Aspartate transaminase 
BNP B-type natriuretic peptide 
CCB Calcium channel blocker 
COPD Chronic obstructive pulmonary disease 
COVID-19 Coronavirus disease 2019 
CRP C-reactive protein 
CT Chest computerized tomography 
cTNI Cardiac troponin I 
cTNT Cardiac troponin T 
DBP Diastolic blood pressure 
DIC Disseminated intravascular coagulation 
HFSA Heart Failure Society of America 
HR Hazard ratio 
hs-cTNI High sensitivity cardiac troponin I 
IQR Interquartile range 
IRDs Incidence rate differences 
ISH International Society of Hypertension 
ISTH International Society on Thrombosis and Hemostasis 
LDL-c Low density lipoprotein cholesterol  
MERS Middle East Respiratory Syndrome 
NT-proBNP N-Terminal pro-brain natriuretic peptide  
OR Odds ratio 
RAS Renin-angiotensin-aldosterone system 
RT-PCR Reverse transcription-polymerase chain reaction 
SaO2 Oxyhemoglobin saturation 
SARS Severe acute respiratory syndrome 
SARS-COV Severe acute respiratory syndrome coronavirus 
SBP Systolic blood pressure 
SD Standardized difference 
ULN Upper limit of normal 
WHO World Health Organization 
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INTRODUCTION 
 
The coronavirus disease 2019 (COVID-19) epidemic is caused by an infection with a novel coronavirus, 
officially named severe acute respiratory syndrome coronavirus 2 (SARS-COV-2).1 Among patients with 
COVID-19 admitted to a hospital, emerging data suggest that hypertension may be associated with an 
increased risk of mortality due to COVID-19.2-4  
 
Angiotensin converting enzyme inhibitor (ACEIs) and angiotensin II receptor blockers (ARBs) are part 
of renin-angiotensin-aldosterone system (RAS) inhibiting agents and considered as one of the first-line 
medications for the management of a large proportion of patients with hypertension.5, 6 However, continued 
use of ACEI/ARB has become controversial in the setting of COVID-19. The reason for this controversy 
stems from the fact that ACEIs and ARBs use may increase the expression of ACE2 receptor in animal-
based studies,7, 8 which is the known cellular receptor and a necessary entry point for SARS-COV-2 
infection9. Conversely, it has been indicated that ACE2 expression is downregulated following SARS 
infection, resulting in excessive activation of RAS and exacerbated pneumonia progression.10 Therefore, 
administration of ACEI/ARB may in turn be beneficial by blocking ACE2 downregulation-induced 
hyperactivation of RAS and thereby preventing acute lung injury and risk of adult respiratory distress 
syndrome. However, due to lack of sufficient clinical data supporting either the beneficial or harmful effects 
of ACEI/ARB use in patients with COVID-19, the optimal strategy for the management of hypertension in 
COVID-19 is uncertain and remains to be elucidated. The aim of this retrospective cohort study was to 
determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 
among patients with hypertension. 
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METHODS 
Materials and data that support the findings of this study are available from the corresponding authors upon 
reasonable request. 
 
Study design and participants. 
This retrospective, multi-center study included 1128 patients with hypertension and COVID-19 infection 
admitted to nine hospitals in Hubei, China, including Renmin Hospital of Wuhan University, Zhongnan 
Hospital of Wuhan University, Wuhan First Hospital, Wuhan Third Hospital, Wuhan Seventh Hospital, 
Wuhan Ninth Hospital, Thunder Mountain Hospital, Huanggang Central Hospital, and the Central Hospital 
of Enshi Tujia and Miao Autonomous Prefecture. The study protocols were approved by central ethics 
committee, and all collaborating hospitals either approved study protocol by local ethics committees or 
accepted the central ethics approval. Patient informed consent was waived by each ethics committee. 
Patients were admitted between December 31, 2019 and February 20th, 2020. The final date of follow up 
was March 7, 2020. 
 
COVID-19 was diagnosed by meeting one or both criteria of chest computerized tomography (CT) 
manifestations and reverse transcription-polymerase chain reaction (RT-PCR) according to the New 
Coronavirus Pneumonia Prevention and Control Program (5th edition) published by the National Health 
Commission of China and WHO interim guidance (Online Table I).11, 12 We used the following inclusion 
and exclusion criteria to determine the study cohort. The inclusion criteria included patients with COVID-
19, aged from 18 to 74 years, who were admitted to the above-mentioned hospitals in Hubei, China from 
December 31st, 2019 to February 20th, 2020. The exclusion criteria included incomplete medical records 
(e.g., transfer to any other hospital), pregnancy, acute lethal organ injury (e.g., acute myocardial infarction, 
acute coronary syndrome, acute pulmonary embolism, or acute stroke), decompensated or end stage of 
chronic organ dysfunction (e.g., decompensated cirrhosis, decompensated chronic renal insufficiency, or 
severe congestive heart failure), acquired immune deficiency syndrome (AIDS), or leukemia or malignancy. 
Patients with hypertension were classified based upon clearly documented medical history with systolic 
blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg.5 
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Data collection. 
Following data were collected including patient demographic information, medical history, clinical 
characteristics, laboratory data, radiologic report data, history of comorbidities, therapeutic interventions 
during the hospitalization, and clinical outcomes. The patient demographic information (age and gender), 
clinical characteristics (fever, cough, fatigue, dyspnea, heart rate, respiratory rate, and blood pressure), and 
durations from symptom onset to admission were collected from electronic medical system. The radiologic 
report data (chest computed tomography [CT]-diagnosed unilateral and bilateral lesions) were obtained 
from picture achieving and communication system. Laboratory data (blood cell count, C-reactive protein 
[CRP], procalcitonin, D-dimer, organ function markers, K+, LDL-c [low density lipoprotein cholesterol], 
SaO2, and blood glucose) were collected from laboratory information system. Comorbidities (hypertension, 
diabetes, coronary heart disease, chronic renal diseases, cerebrovascular diseases, chronic liver disease, and 
chronic obstructive pulmonary disease) were extracted from medical history. The in-hospital medications 
and interventions were collected from doctor advices. Personal health identifying information (e.g., name 
and ID) was anonymized and each participant was given a study ID using an electronic coding system 
before data extraction to preserve patient privacy. Data were carefully reviewed and confirmed by 
experienced physicians and were double-checked to guarantee the accuracy of the data extraction 
procedures. 
 
Definition. 
The onset of COVID-19 was defined as the time point when the symptoms were first noticed. Patients with 
hypertension who received ACEI/ARB during hospitalization were classified as ACEI/ARB group. Patients 
with hypertension who did not receive ACEI/ARB during hospitalization were classified as non-ACEI/ARB 
group. In the subgroup propensity score-matched cohort analysis among patients taking antihypertensive 
medications, participants taking ACEI/ARB and other antihypertensive drugs (non-ACEI/ARB) during in-
hospital stay were included. Patients discontinued treatment of hypertension due to inability to take 
medications (e.g., hypotension, mechanical ventilation without nasal feeding and unable to orally taking 
medicines, or increase of creatinine level) during hospitalization were still included from the cohort. The 
primary endpoint was defined as 28-day all-cause death. ARDS and septic shock were defined according 
to the WHO interim guideline “Clinical management of severe acute respiratory infection when novel 
coronavirus (2019-nCoV) infection is suspected”13 (Online Table I). Acute kidney injury was defined as 
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an elevation in serum creatinine level equal or above 26.5 µmmol/L within 48 hours.14 Cardiac injury was 
defined as the serum level of cardiac troponin I (cTNI), cardiac troponin T (cTNT), or high sensitivity 
cardiac troponin I (hs-cTNI) above the upper limit of normal (ULN). Disseminated intravascular 
coagulation (DIC) was defined according to the criteria defined by the International Society on Thrombosis 
and Hemostasis (ISTH).15 The increase in blood cell count and biochemical indexes were defined as over 
their ULN according to the criteria by the laboratory standards in each hospital (ULNs for CRP, 
procalcitonin, creatinine, D-dimer and platelets were shown in Online Table II). 
 
Propensity score-matched analysis. 
Propensity score-matched cohorts were created based on variables which were expected to be potential 
confounders associated with exposure to ACEI/ARB, including age, gender, fever, cough, dyspnea, 
comorbidities (diabetes, coronary heart disease, and chronic renal disease), CT-diagnosed bilateral lung 
lesions, and incidence of increased CRP and creatinine. We adjusted for imbalanced variables (D-dimer, 
procalcitonin, and unilateral lesion) and in-hospital medications (antiviral drug and lipid lowering drug) 
between ACEI/ARB versus non-ACEI/ARB groups in following mixed-effect Cox model. We used non-
parametric missing value imputation, based on the missForest procedure in the R, to account for missing 
data on the laboratory variable of increased creatinine, CRP levels, procalcitonin, D-dimer, and unilateral 
lesion.16 A random forest model using the rest of the variables in the data set was performed to predict the 
missing values for these variables. The internally cross-validated errors were also estimated. ACEI/ARB 
and non-ACEI/ARB users were paired according to the propensity scores using exact matching with a 
caliper size of 0.05. The balance of covariates was evaluated by estimating standardized differences (SD) 
before and after matching, and small absolute value less than 0.1 was considered successful balancing 
between the two groups. For cohort analysis in all patients with hypertension, and in those treated with 
antihypertensive therapies, ACEI/ARB and non-ACEI/ARB ratios were paired at 1:2 and 1:1, respectively.  
 
Statistical analysis. 
Continuous variables were expressed as median and interquartile range (IQR), and categorical variables 
were expressed as number and percentage (%). Statistical differences between two groups were analyzed 
using the Mann-Whitney U test for continuous variables, while categorical variables were compared using 
Fisher’s exact test or  χ2 test. The risk of composite endpoints and corresponding hazard ratio (HR) were 
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calculated using the Cox proportional hazard model comparing ACEI/ARB group vs. non-ACEI/ARB 
group. Multi-variable adjusted including age, gender, comorbidities (diabetes, coronary heart disease, 
cerebrovascular disease, and chronic renal disease), and in-hospital medications (antiviral drug and lipid 
lowering drug) were performed. We modeled site as a random effect in the mixed-effect Cox model. The 
proportional hazard assumptions were verified using correlation testing based on Schoenfeld residuals. 
Incidence rate differences (IRDs) were calculated to provide incidence difference on absolute change. The 
cumulative rates of death were compared using the Kaplan-Meier method. A two-side α less than 0.05 was 
considered statistically different. Because of the potential for type 1 error due to multiple comparisons, 
findings for analyses of secondary endpoints should be interpreted as exploratory. Data were analyzed in 
R-3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS Statistics (version 23.0, IBM, 
Armonk, NY, USA). 
 
Sensitivity analysis. 
E-value analysis was conducted to assess the robustness of the association between ACEI/ARB use and all-
cause mortality in the mixed-effect Cox model to address unmeasured confounding using the methodology 
of VanderWeele and Ding.17-19 The E-value is an alternative approach to sensitivity analyses for unmeasured 
confounding in our studies that avoids making assumptions that, in turn, require subjective assignment of 
inputs for some formulas. If the strength of unmeasured confounding is weaker than indicated by the E-
value, then the main study result could not be overturned to one of the unmeasured confounder. E-values 
can therefore help to assess the robustness of the main study result by considering whether unmeasured 
confounding of this magnitude is plausible. We performed two sensitivity analyses to evaluate the 
robustness of propensity score-matched cohort analyses, among all patients with hypertension, using pairs 
of 1:2. In the first sensitivity analysis, comorbid diabetes was not included in matching, while the second 
sensitivity analysis was conducted adding cerebrovascular disease as a matching variable. We conducted a 
subset analysis restricted to patients who were taking an anti-hypertensive medication, applying matching 
variables as above with the pairing ratio at 1:1.  
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RESULTS  
 
Participants. 
This study cohort included 3611 patients with COVID-19 who were admitted to these nine hospitals 
in Hubei, China. After excluding 181 participants following our exclusion criteria, 3430 participants 
comprising 1128 hypertensive and 2302 normotensive cases were included in subsequent analysis (Figure 
1; Online Table III). Among the 1128 participants with hypertension and COVID-19, 188 were classified 
as ACEI/ARB group (median age 64 [IQR 55-68] years; 53.2% men) and the remaining 940 were classified 
as non-ACEI/ARB group (median age 64 [IQR 57-69]; 53.5% men). The characteristics of the ACEI/ARB 
group versus the non-ACEI/ARB group on admission were provided in Table 1. Compared to the 
ACEI/ARB group, the non-ACEI/ARB group had higher prevalence of fever, dyspnea, and bilateral lung 
lesion at presentation. The dynamic changes in blood pressure during a 28-day follow-up period after 
presentation were similar between the ACEI/ARB and non-ACEI/ARB groups (Online Figure I). In terms 
of in-hospital treatment, the ACEI/ARB group had a higher percentage of patients receiving antiviral (88.8% 
vs. 81.7%; P = 0.02) and lipid-lowering therapies (22.9% vs. 10.0%; P = 1.51E-6) than patients in the non-
ACEI/ARB group (Table 2).  
 
Primary outcomes. 
During a 28-day follow-up duration, 99 deaths died out of the 1128 patients with hypertension and 
COVID-19. The risk of 28-day all-cause mortality was significantly lower in ACEI/ARB group versus non-
ACEI/ARB group (3.7% [7/188] vs. 9.8% [92/940]; P = 0.01). In the mixed-effect Cox model using site as 
a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications (antiviral and 
lipid lowering drugs), use of ACEI/ARB was associated with lower all-cause mortality (adjusted HR, 0.42; 
95% CI, 0.19-0.92; P = 0.03) versus use of non-ACEI/ARB (Figure 2A and Table 3). The E value for the 
point estimate of primary endpoint was 4.22 with upper limit of CI at 1.41. In our study, the adjusted hazard 
ratios (HR) for association of known variables for all-cause mortality due to COVID-19 were 1.08 (95%CI, 
1.04-1.11; P = 3.30E-6) for age, 2.23 (95%CI, 1.45-3.43; P = 2.78E-4) for gender, 1.47 (95%CI, 0.86-2.52; 
P = 0.16) for coronary heart disease, and 1.35 (95%CI, 0.58-3.16; P = 0.49) for cerebrovascular disease. 
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 We further conducted a propensity score-matched analysis to account for confounding that may have 
resulted in a protective association between ACEI/ARB use and all-cause mortality. We successfully 
matched 174 patients with hypertension in the ACEI/ARB group to non-ACEI/ARB group at a ratio of 1:2, 
and 522 individuals were included in the propensity score-matched samples. Imbalanced in-hospital 
medications (antiviral drug and lipid lowering drug), increase of D-dimer, and unilateral lung lesion after 
matching were adjusted in mixed-effect Cox model using site as a random effect. The results remained 
consistent and statistically significant, demonstrating lower risk of all-cause mortality in patients who 
received ACEI/ARB (adjusted HR, 0.37; 95%CI, 0.15-0.89; P = 0.03) versus those who did not receive 
ACEI/ARB using this propensity score-matched analysis (Figure 2B and Table 3). To further assess the 
robustness of the association between ACEI/ARB use and mortality, we performed additional sensitivity 
analyses by using different matching variables. The results remained consistent and statistically significant 
in these sensitivity analyses with HRs of 0.34 (95%CI, 0.14-0.82; P = 0.02) in the first sensitivity analysis 
and of 0.33 (95% CI, 0.13-0.80; P = 0.01) in the second analysis. 
 
Since there were 34.0% patients with hypertension who did not receive antihypertensive drugs during 
hospitalization, we performed subgroup propensity score-matching analysis on the remaining 745 patients 
who received at least one anti-hypertensive medication during hospitalization to further minimize the 
potential bias from non-users. One hundred eighty-one patients using ACEI/ARB versus those using other 
anti-hypertensive drugs were paired at 1:1. Characteristics of matched and unmatched participants in this 
analysis were listed in Online Table IV. The results demonstrated that the in-hospital use of ACEI/ARB 
was associated with lower risk of all-cause mortality (adjusted HR, 0.29; 95%CI, 0.12-0.69; P = 0.005) due 
to COVID-19 (Online Figure II and Online Table V). This association was further supported by sensitivity 
analyses with adjusted HR of 0.29 (95% CI, 0.12-0.70; P = 0.01) in the first sensitivity analysis not 
including diabetes as a matching variable and of 0.30 (95%CI, 0.13-0.71; P = 0.01) in the second sensitivity 
analysis adding cerebrovascular disease as a matching variable.  
 
Secondary outcomes. 
The incidence of septic shock (3.2% in ACEI/ARB vs. 8.0% in non-ACEI/ARB [P = 0.03]; IRD, -
0.19 [95%CI, -0.36 – -0.01]) and DIC (0.0% vs. 2.3%, P = 0.04; IRD, -0.23 [95%CI, -0.52 – 0.07]) were 
lower in the ACEI/ARB group than the non-ACEI/ARB group (Table 3). In the mixed-effect Cox model, 
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use of ACEI/ARB was associated with lower risk of septic shock (adjusted HR, 0.36; 95% CI, 0.16-0.84; 
P = 0.01) compared to non-ACEI/ARB group (Table 3).  
 
In propensity score-matched cohort analysis, the risk of septic shock was lower in ACEI/ARB group 
(adjusted HR, 0.32 [95%CI, 0.13-0.80; P = 0.01]; IRD, -0.20[95%CI, -0.39 – -0.01]) than non-ACEI/ARB 
group among all individuals with hypertension (Table 3). In a sub-group of patients, who received at least 
one anti-hypertensive medication during hospitalization, the findings remained consistent (adjusted HR, 
0.24 [95%CI, 0.10-0.63; P = 0.003]; IRD, -0.31 [95%CI, -0.54 – -0.09]) (Online Table V).  
 
Comparison of patients with hypertension vs non-hypertension. 
Compared to patients in the normotensive group, the hypertensive group had a higher percentage of 
dyspnea, comorbidities, and abnormal laboratory markers on admission, and they received more intensive 
in-hospital interventions (Online Table III and Online Table VI). During the 28-day follow-up period, 
co-existing hypertension was significantly associated with the higher risk of all-cause mortality (adjusted 
HR, 1.41; 95% CI, 1.03-1.94; P = 0.03) and the occurrence of multi-organ injury (Online Figure III and 
Online Table VII).  
 
 
DISCUSSION 
 
In this multicenter retrospective study, in-hospital use of ACEI/ARB was associated with lower risk 
of all-cause mortality due to COVID-19 compared with either nonuse of ACEI/ARB or use of a different 
class of anti-hypertensive agent among patients with hypertension. Although it is plausible that unmeasured 
confounding may have contributed to the observed protective association, these data suggest that in-hospital 
use of ACEI/ARB was not associated with increased mortality in COVID-19. These findings provide 
clinical evidence in support of recently published guidance statements by several international societies to 
continue ACEI/ARB in patients with COVID-19 20, 21. Given the retrospective nature of this study, these 
data need further validation in geographically diverse, prospective, cohort studies. Randomized controlled 
trials are needed to examine the efficacy of ACEI/ARB use in patients with hypertension and COVID-19.  
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 Previous clinical studies have shown that hypertension is a risk factor for higher mortality in patients 
suffering from SARS and Middle East Respiratory Syndrome (MERS).22-24 Similar to the association 
between hypertension and other previous outbreaks from novel coronavirus infections, recent studies in 
patients with COVID-19 have also reported that hypertension is associated with higher mortality in 
COVID-19 compared to normotensions.3, 4 The underlying pathogenic mechanism linking hypertension and 
severity of COVID-19 infection remains to be elucidated. It has been hypothesized that excessive activation 
of RAS system might contribute to progression of COVID-19 related lung injury by promoting 
inflammatory response and cytokine storm,25 stimulating the NADH/NADPH oxidase system,26 and 
triggering cell contraction and vasoconstriction27. Further studies are needed to better understand the 
underlying biological mechanisms involved in the association between hypertension and adverse outcomes 
in COVID-19.    
 
 In the management of COVID-19 patients with hypertension, use of ACEI and ARB has been a 
contentious issue. These therapeutic effects involve ACE2, a known cellular receptor of SARS-COV-2 
which is required for viral entry and propagation in host cells. ACEI and ARB treatment can increase ACE2 
expression in animal-based studies.7, 8 Potentially, ACEI/ARB might increase ACE2 expression, thus 
promoting SARS-COV-2 susceptibility and disease severity of COVID-19. Conversely, ACE2 negatively 
regulates RAS and serves as a counterbalance to ACE function. Its expression is significantly 
downregulated after SARS-COV infection, contributing to hyper-activated RAS cascades.28 As a 
consequence, loss of ACE2 in mice confers resistance to SARS-COV infection, but also results in 
exacerbated vascular permeability, lung edema, neutrophil accumulation, and pulmonary dysfunction.10, 29 
Recombinant ACE2 protein protects against acute lung injury in mouse models of ARDS and SARS. A 
retrospective review of 539 consecutive hospitalized patients with viral pneumonia indicates that continuing 
in-hospital use of ACEI or ARB may reduce the risk of pneumonia and death (ACEI, OR, 0.64 for risk of 
pneumonia; OR, 0.25 for in-hospital death; ARB, OR, 0.48 for risk of pneumonia; OR, 0.75 for in-hospital 
death).30 A more recent study by Liu et al. shows that plasma AngII concentration is significantly elevated 
after SARS-COV-2 infection.31 the influence of ACEI/ARB on COVID-19 related outcomes has not been 
fully investigated. Furthermore, among patients with COPD, it has been suggested that ARB might be more 
effective than ACEI to reduce the severity and mortality due to COPD.32 This study was not powered to 
assess the differential beneficial effects of ACEI versus ARB versus combination of ACEI and ARB in 
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improving outcomes in COVID-19. The differential efficacy of ACEI and ARB use in improving COVID 
related outcomes also needs to be examined in further studies. 
 
A statement jointly published by American Heart Association (AHA), the Heart Failure Society of 
America (HFSA) and the American College of Cardiology (ACC),20 and another statement from the 
International Society of Hypertension (ISH) on COVID-19 21 strongly recommended continuation of ACEI 
or ARB among patients with co-existing hypertension and COVID-19. The main argument in favor of 
continuation of ACEI/ARB was that there are no clinical data to show whether ACEI and ARB would either 
improve or worsen COVID19. Therefore, it is not recommended to modify or change antihypertensive 
therapy before fully evaluating the possible influence of ACEI/ARB among patients with COVID-19. Our 
findings in this paper provide evidence supporting continuous use of ACEI/ARB for patients with 
hypertension infected with SARS-COV-2. Comorbidities and in-hospital medications might lead 
confounding to the association between ACEI/ARB application with COVID-19 mortality. Previous studies 
have suggested that hypokalemia may be a marker of unopposed Ang II,33, 34 and therefore, hypokalemia 
may modify the association between anti-hypertensive therapy and outcomes in COVID-19 infection. 
Further studies are needed to examine the role of hypokalemia and hypertension and ACEI/ARB use and 
its influence on COVID-19 severity. The protection effect of ACEI/ARB also may result from the favorable 
effect on microvascular complications, thus reduces cardiovascular and renal morbidity.35, 36 
 
Overall, these findings suggested potential beneficial effects observed with continued use of 
ACEI/ARB therapy and the possible contribution of RAS activation in the pathogenesis of severity of 
COVID-19 in patients with hypertension. Considering the impact of unmeasured potential confounders, we 
conducted E-value analysis and found that E value was substantially greater than accepted risk factors for 
COVID-19 mortality. Therefore, it is not likely that an unmeasured confounder exists to modify the 
conclusion that ACEI/ARB use was not associated with increased COVID-19 mortality as observed in this 
study. 
 
Limitations. 
This study has several limitations. First, the study population originated from nine hospitals in Hubei 
Province and may reflect natural history of hospitalized patients with COVID-19. It is plausible that the 
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beneficial effects of ACEI/ARB may be different among patients who are managed in the outpatient setting 
or in ethnically or geographically diverse populations. Second, the study sample-size was modest and 
included 188 patients who received ACEI/ARB. It did not have the power to detect if there was a differential 
effect between ACEI and ARB. Third, since the retrospective nature of this study, some parameters were 
not available in all patients, and in-hospital medications might be not fully recorded. For instance, some 
patients with hypertension may have failed to report antihypertensive medication though self-
administration (e.g., Traditional Chinese Medicines) or might stop antihypertensive medication due to well-
controlled blood pressure. Fourth, application of antihypertensive drugs was not matched or adjusted when 
comparing ACEI/ARB and non-ACEI/ARB groups since it is a key comparative factor for outcomes. The 
differences in proportions of patients using beta-locker and diuretics between ACEI/ARB and non-
ACEI/ARB groups might induce unappreciated confounding to conclusion. Fifth, this study was not able 
to retrieve pre-hospital self-medications from in-hospital electronic record systems in the urgent 
circumstance of the COVID-19 pandemic, and thus was unable to account for their influence on the severity 
of presentation and outcomes. Therefore, large-scale prospective cohort studies and randomized controlled 
trials are needed in ethnically and geographically diverse cohorts to better understand the association 
between ACEI/ARB and survival in COVID-19. 
 
Conclusions. 
Among patients with hypertension hospitalized with COVID-19, inpatient treatment with ACEI/ARB 
was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. While study 
interpretation needs to consider the potential for residual confounders, it is unlikely that inpatient 
ACEI/ARB would be associated with an increased risk of mortality. 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
• Hypertension is the most common comorbidity of the coronavirus disease 2019 (COVID-19) and had 
been suggested to be associated with increased mortality. 
 
• Angiotensin converting enzyme inhibitor (ACEIs) and angiotensin II receptor blockers (ARBs) are 
first-line medications for a large proportion of patients with hypertension.  
 
• Use of ACEI/ARB is a major concern for clinicians in treating COVID-19 patients with hypertension 
because of the potential effect of ACEI/ARB on increasing the expression of ACE2, the binding 
receptor and entry point of the coronavirus. 
 
What New Information Does This Article Contribute? 
• The incidence of the 28-day all-cause death among patients who had inpatient treatment with 
ACEI/ARB is significant lower compared with ACEI/ARB non-users, based on the analysis of 1128 
hospitalized COVID-19 patients with hypertension. 
 
• After matching and adjusting variables may interfering the effect of ACEI/ARB, in-hospital use of 
ACEI/ARB still exhibits remarkable association with reduced all-cause mortality of COVID-19 
patients with hypertension. 
 
• These findings clearly support recently published recommendations regarding continuation of ACEI 
or ARB among patients with co-existing hypertension and COVID-19. 
 
Application of ACEI/ARB is a one of major concerns in treating COVID-19 among patients with 
hypertension, for the possible increased risk by ACEI/ARB on increased ACE2, a direct receptor and entry 
point of SARS-COV-2. However, the association between ACEI/ARB and COVID-19 mortality in patients 
with hypertension is largely unknown. Here, the multicentered retrospective cohort study indicated that in-
hospital use of ACEI/ARB is associated reduced 28-day all-cause mortality of COVID-19 compared to 
non-ACEI/ARB group in patients with hypertension. Findings in this study provide direct clinical data to 
show the potential benefit of ACEI/ARB in treating patients with hypertension and hospitalized with 
COVID-19 and support the continuous use of ACEI/ARB in those patients as recently recommend by 
societies. 
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FIGURE LEGENDS 
Figure 1. The flowchart showing the strategy of participant enrollment.  
a, 1128 participants with a history of hypertension enrolled in the hypertension cohort. 
b, 2302 participants without a history of hypertension enrolled in the non-hypertension cohort. 
c, 188 patients with hypertension who taking ACEI and/or ARB during hospitalization were enrolled in the 
ACEI/ARB cohort. Patients discontinued treatment of hypertension due to inability to take medications or 
hypotension were not excluded from the cohort. 
d, 940 patients with hypertension who never taking ACEI and ARB during hospitalization were enrolled in 
the non-ACEI/ARB cohort. 
e, Propensity score-matched age, gender, cough, dyspnea, comorbidities (diabetes, coronary heart disease 
and chronic renal disease), CT-diagnosed lung lesions, and incidence of increased CRP and creatine. 
Hospital site as a random effect in the mixed-effect Cox model. 
f, 557 patients with antihypertension drug who never taking ACEI and ARB during hospitalization were 
enrolled in the secondary non-ACEI/ARB cohort. 
 
Figure 2. Kaplan-Meier Curves for cumulative probability of COVID-19 mortality during 28-day follow-
up duration in ACEI/ARB or non-ACEI/ARB cohort among 1128 patients with hypertension in unmatched 
model. The median (IQR) observation time was 28(20-28) in ACEI/ARB cohort and 28(19-28) in non-
ACEI/ARB cohort (A). Propensity-score matched model and the median (IQR) observation time was 
28(20.5-28) in ACEI/ARB cohort and 28(18-28) in non-ACEI/ARB cohort (B). The blips indicate 
censoring.  
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Table 1 Characteristics of patients with hypertension in ACEI/ARB and non-ACEI/ARB groups before and after propensity score matching.  
 Unmatched  Matched (1:2) 
Parameters ACEI/ARB
† 
(n = 188) 
Non-ACEI/ARB‡ 
(n = 940) SD
§  ACEI/ARB
† 
(n = 174) 
Non-ACEI/ARB‡ 
(n = 348) SD
§ 
Clinical characteristics on admission        
Age, median(IQR) 64 (55-68) 64 (57-69) -0.035  64(56-68) 64(56-69) -0.046 
Male gender, n (%) 100(53.2) 503(53.5) -0.006  94(54.0) 197(56.6) -0.052 
Female gender, n (%) 88(46.8) 437(46.5) 0.006  80(46.0) 151(43.4) 0.052 
Heart rate, median(IQR) 82.0(76.0-95.3) 84.0(78.0-96.0) -0.062  82(76-94) 82(77-94) -0.004 
Respiratory rate, median(IQR) 20.0(19.0-21.0) 20.0(19.0-22.0) -0.049  20(19-21) 20(18-21) 0.013 
SBP, median(IQR) 132.5(123.0-145.8) 132.0(120.0-144.0) 0.064  134(124-148) 132(121-145) 0.027 
DBP, median(IQR) 80.0(72.0-87.8) 80.0(72.0-88.0) -0.020  80(74-88) 80(73-87) 0.072 
Symptom onset to admission, median(IQR), 
day 
10.0(7.0-15.0) 10.0(7.0-15.0) -0.055  10(7-15) 10(7-15) -0.111 
Fever, n(%) 126(67.0) 700(74.5) -0.164  120(69.0) 235(67.5) 0.031 
Cough, n(%) 122(64.9) 653(69.5) -0.098  111(63.8) 223(64.1) -0.006 
Fatigue, n(%) 65(34.6) 363(38.6)  -
0.084 
 
60(34.5) 131(37.6) -0.066 
Dyspnea, n(%) 38(20.2) 260(27.7) -0.175  34(19.5) 66(19.0) 0.015 
Comorbidities on admission        
Diabetes, n(%) 44(23.4) 196(20.9)  -
0.062 
 
40(23.0) 86(24.7) -0.040 
Coronary heart disease, n(%) 29(15.4) 102(10.9) 0.136  24(13.8) 46(13.2) 0.017 
Chronic renal diseases, n(%) 7(3.7) 28(3.0) 0.041  7(4.0) 11(3.2) 0.046 
Cerebrovascular diseases, n(%) 5(2.7) 36(3.8) -0.066  4(2.3) 8(2.3) 0.000 
Chronic liver disease, n(%) 4(2.1) 17(1.8) 0.023  4(2.3) 5(1.4) 0.064 
Chronic obstructive pulmonary disease, 
n(%) 
1(0.5) 5(0.5) 0.000  
1(0.6) 1(0.3) 0.044 
Chest CT on admission        
Unilateral lesion, n/N(%) 16/173(9.3) 42/895(4.7) 0.180  13/159(8.2) 18/329(5.5)  0.107 
Bilateral lesions, n/N (%) 146/173(84.4) 795/895(88.8) -0.130  137/159(86.2) 284/329(86.3) -0.005 
Laboratory examination on admission        
Leukocyte count > 9.5, 10^9/L, n/N (%) 22/183(12.0) 101/883(11.4) 0.018  20/170(11.8) 32/325(9.9) 0.062 
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Neutrophil count > 6.3, 9.5 10^9/L ,n/N (%) 32/183(17.5) 179/882(20.3) -0.072  28/170(16.5) 64/324(19.8) -0.085 
Lymphocyte count < 1.1, 9.5 10^9/L, n/N 
(%) 
82/183(44.8) 426/883(48.2) -0.069  
77/170(45.3) 157/325(48.3) -0.060 
        
 Unmatched  Matched (1:2) 
Parameters 
ACEI/ARB† 
(n = 188) 
Non-ACEI/ARB‡ 
(n = 940) SD§ 
 ACEI/ARB† 
(n = 174) 
Non-
ACEI/ARB‡ 
(n = 348) 
SD§ 
C-reactive protein increase>ULN*, n/N (%) 78/133(58.7) 443/641(69.1) -0.219  74/124(59.7) 136/221(61.5) -0.038 
Procalcitonin level increase> ULN*, n/N (%) 40/144(27.8) 237/727(32.6) -0.105  38/134(28.4) 83/266(31.2) -0.062 
ALT increase> 40 U/L, n/N (%) 33/179(18.4) 170/877(19.4) -0.024  30/166(18.1) 52/323(16.1) 0.052 
AST increase> 40 U/L, n/N (%) 40/179(22.4) 247/877(28.2 -0.134  37/166(22.3) 79/323(24.5) -0.051 
Creatinine>ULN*, n/N (%) 14/166(8.4) 92/845(10.9) -0.083  11/153(7.2) 25/308(8.1) -0.035 
D-dimer> ULN*, n/N (%) 67/149(45.0) 392/743(52.8) -0.156  63/137(46.0) 140/273(51.3) 0.106 
K+ < 3.5 mmol/L, n/N (%) 51/179(28.5) 233/873(26.7) 0.040  47/166(28.3) 88/323(27.2) 0.024 
Platelets < ULN*, n/N (%) 22/183(12.0) 106/883(12.0) 0.000  21/170(12.35) 44/325(13.54) -0.733 
LDL-c, mmol/L, median (IQR) 2.2(1.8-2.8) 
[n = 151] 
2.3(1.8-2.8) 
[n = 721] 
-0.010  2.2(1.8-2.8) 
[n = 140] 
2.2(1.8-2.7) 
[n = 257] 
0.042 
SaO2, <95%, n/N (%) 30/138(21.7) 146/692(21.1) 0.016  28/125(22.4) 53/254(20.9) 0.037 
Blood glucose, median (IQR), mmol/L 6.0(5.1-8.3) 
[n = 163] 
6.2(5.2-8.4) 
[n = 803] 
-0.011  6(5.1-8.3) 
[n = 151] 
6.2(5.3-8.7) 
[n = 298] -0.047 
 
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SBP, Systolic blood pressure; DBP, Diastolic 
blood pressure; COPD, Chronic obstructive pulmonary disease; ALT, alanine transaminase; AST, Aspartate transaminase; IQR, Interquartile range; 
SD, Standardized difference. 
*Upper limit of normal (ULN) was defined according to criteria in each hospital and normal ranges of tests in each hospital were provided in Online 
Table II. Increase or decrease in a biomarker indicates the number of patients have increased or decreased levels of biomarker at baseline. 
†Patients with hypertension who taking ACEI and/or ARB during hospitalization were enrolled in the ACEI/ARB cohort. Patients discontinued 
treatment of hypertension due to inability to take medications or hypotension were not excluded from the cohort. 
‡Patients with hypertension who never taking ACEI and ARB during hospitalization were enrolled in the non-ACEI/ARB cohort. 
§SD, Standardized differences be used to compare the mean of baseline covariate between ACEI/ARB and non-ACEI/ARB group. 
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Table 2 In-hospital management of ACEI/ARB and non-ACEI/ARB groups. 
Treatment ACEI/ARB
* 
(n = 188) 
Non-ACEI/ARB† 
(n = 940) 
Absolute 
difference 
(95% CI), % 
P value‡ 
Traditional Chinese medicine n 
(%) 
171(91.0) 807(85.9) 5.1(-0.2 to 10.4) 0.08 
Antiviral drug, n (%) 167(88.8) 768(81.7) 7.1(1.2 to 13.0) 0.02 
Antibiotics drug, n (%) 144(76.6) 718(76.4) 0.2(-6.4 to 6.9) 0.99 
Nasal cannula oxygen inhalation§, 
n (%) 
142(75.5) 745(79.3) -3.7(-10.1 to 2.7) 0.30 
Systemic corticosteroids, n (%) 66(35.1) 380(40.4) -6.2(-13.9 to 1.5) 0.20 
Antidiabetic drug, n (%) 55(29.3) 226(24.0) 5.2(-1.6 to 12.0) 0.16 
Lipid lowering drug, n (%) 43(22.9) 94(10.0) 12.8(7.8 to 18.0) 1.51E-6 
Immunoglobin, n (%) 51(27.1) 279(29.7) 21.2(16.7 to 25.6) 0.54 
Vasoactive drug, n (%) 18(9.6) 106(11.3) -1.7(-6.6 to 3.2) 0.58 
Noninvasive ventilation||, n (%) 15(8.0) 20(11.4) 5.9(3.1 to 8.6) 0.21 
Invasive ventilation||, n (%) 9(5.0) 51(5.4) 3.5(1.4 to 5.6) 0.86 
Antifungal medications, n (%) 7(3.7) 40(4.3) -0.5(-3.7 to 2.6) 0.89 
Renal replacement therapy, n(%) 1(0.5) 14(1.5) 0.1(-0.9 to 1.2) 0.49 
Extracorporeal membrane 
oxygenation||, n (%) 
0(0.0) 4(0.4) -0.4(-1.4 to 0.5) 1.00 
Diuretic, n (%) 58(30.9) 120(12.8) 18.1(12.4 to 23.8) 1.06E-9 
CCB, n (%) 103(54.8) 489(52.0) 2.8(-5.1 to 10.6) 0.54 
beta-blocker, n (%) 53(28.2) 168(17.9) 10.3(4.1 to 16.5) 0.002 
alpha-blocker, n (%) 4(2.1) 21(2.2) -0.1(-2.4 to 2.2) 1.00 
ACEI, n (%) 31(16.5) 0(0.0) 16.5(13.9 to 19.1) 3.34E-35 
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ARB, n (%) 157(83.5) 0(0.0) 83.5(78.1 to 88.9) 8.16E-199 
*Patients with hypertension who taking ACEI and/or ARB during hospitalization were enrolled in the ACEI/ARB cohort. Nine patients in ACEI/ARB 
group were taken off ACEI/ARB due to hypotension (2 cases), mechanical ventilation without nasal feeding and unable to orally taking medicines 
(1 case), and increased creatinine level (> 1.5-fold of ULN; 6 cases). These patients were still included in ACEI/ARB group. Patients placed on 
ACEI/ARB on admission were included in the ACEI/ARB group. 
†Patients with hypertension who never taking ACEI and ARB during hospitalization were enrolled in the non-ACEI/ARB cohort. 
‡The P value was calculated by Fisher’s exact test or  χ2 test. 
§Nasal cannula oxygen inhalation was taken in isolation. 
||Noninvasive ventilation, invasive ventilation, and extracorporeal membrane oxygenation are at mutually exclusive. 
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Table 3 Hazard ratios and incidence rate ratios for outcomes in ACEI/ARB group versus non-ACEI/ARB group under mixed-effect Cox model and 
propensity score-matching model 
 
 Unmatched  Matched (1:2) † 
  Crude  Mixed-effect Model*  Mixed-effect Model 
ACEI/ARB vs non-
ACEI/ARB 
IRD (100 Person-
Day) (95%CI) HR(95%CI) 
P 
value§  HR(95%CI) P value
||  IRD (100 Person-Day) (95%CI) HR(95%CI) P value
|| 
All-cause mortality -0.24(-0.43,-0.05) 
0.37(0.17,0.79
) 
0.01  0.42(0.19,0.92) 
0.03 
 -0.27(-0.48,-0.07) 0.37(0.15-0.89) 0.03 
Septic shock -0.19(-0.36,-0.01) 
0.38(0.17,0.87
) 
0.02  0.36(0.16,0.84) 
0.02 
 -0.20(-0.39,-0.01) 0.32(0.13-0.80) 0.01 
ARDS -0.23(-0.52,0.07) 
0.70(0.47,1.02
) 
0.06  0.69(0.47,1.02) 
0.06 
 -0.32(-0.65,0.01) 0.65(0.41-1.04) 0.07 
DIC -0.09(-0.19,0.00) 0.04(0.0, 4.50) 0.18  -‡ - ‡  -0.10(-0.19,0.00) -‡ -‡ 
Acute kidney injury 0.05(-0.10,0.20) 
1.17(0.60,2.25
) 
0.65  1.03(0.51,2.07) 
0.94 
 -0.04(-0.23,0.16) 0.78(0.37-1.65) 0.52 
Acute heart injury -0.10(-0.29,0.08) 
0.91(0.57,1.45
) 
0.70  0.89(0.55,1.44) 
0.64 
 0.00(-0.27,0.27) 0.76(0.44-1.32) 0.33 
 
Abbreviations: HR, Hazard ratio; CI, Confidence interval; IRD, Incidence rate differences, an absolute difference in the incidence between two 
groups. 
*The mixed-effect Cox model is a conditional model including a random per-center effect. Unmatched were adjusted for age, gender, comorbidities 
(diabetes, coronary heart disease, cerebrovascular disease, and chronic renal disease), and in-hospital medications (antiviral drug and lipid lowering 
drug). 
†In the mixed-effect Cox model after propensity score matching, age, gender, cough, dyspnea, comorbidities (diabetes, coronary heart disease and 
chronic renal disease), CT-diagnosed lung lesions, and incidence of increased CRP and creatinine were matched. Modeled center as a random effect 
in the multivariate analyses followed by adjustment for antiviral drug, lipid lowering drug, D-dimer, and unilateral lesion. 
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‡The incidence of DIC was 0 in the ACEI/ARB cohort. HR in DIC was not calculated. 
§P values were calculated based on Cox proportional hazard model. 
||P values were calculated based on mixed-effect Cox model. 
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